Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMOSOUTH SAN FRANCISCO, Calif., Oct. 23, 2026…

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)